Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

hydroxyurea

View Patient Information
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HYD
Hydroxycarbamide
Hydurea
US brand name:Droxia
Hydrea
Foreign brand name:Litalir
Onco-Carbide
Oxeron
Syrea
Abbreviation:HU
Code name:SQ 1089
SQ-1089
WR 83799
IND number:38558
7179
9235
937
NSC code:32065
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search